Safety of immunosuppressive drugs used as maintenance therapy in kidney transplantation: A systematic review and meta-analysis

Pharmaceuticals

Volumn 6, Issue 10, 2013, Pages 1170-1194

  Almeida, Celline Cardoso ^a   Silveira, Micheline Rosa ^a   De Araújo, Vânia Eloisa ^a   De Lemos, Livia Lovato Pires ^a   De Oliveira Costa, Juliana ^a   Reis, Carlos Augusto Lins ^a   De Assis Acurcio, Francisco ^a   Das Gracas Braga Ceccato, Maria ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Adverse events; Immunosuppressive drugs; Kidney transplantation; Meta analysis

Indexed keywords

EID: 84885080864     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph6101170     Document Type: Article

References (78)

1. Levey, A.S.; Coresh, J.; Balk, E.; Kausz, A.T.; Levin, A.; Steffes, M.W.; Hogg, R.J.; Perrone, R.D.; Lau, J.; Eknoyean, G. National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann. Intern. Med. 2003, 139, 137-147.
2. Coresh, J.; Selvin, E.; Stevens, L.A.; Manzi, J.; Kusek, J.W.; Eggers, P.; van Lente, F.; Levey, A.S. Prevalence of chronic kidney disease in the United States. JAMA 2007, 298, 2038-2046.
3. Zhang, Q.L.; Rothenbacher, D. Prevalence of chronic disease in population-based studies: Systematic review. BMC Public Health 2008, 8, 117.
4. Nagata, M.; Ninomiya, T.; Doi, Y.; Yonemoto, K.; Kubo, M.; Hata, J.; Tsuruya, K.; Iida, M.; Kiyohara, Y. Trends in the prevalence of chronic kidney disease and its risk factors in a general Japanese population: The Hisayama study. Nephrol. Dial. Transplant. 2010, 25, 2557-2564.
5. Van Pottelbergh, G.; Bartholomeeusen, S.; Buntinx, F.; Degryse, J. The prevalence of chronic kidney disease in a Flemish primary care morbidity register. Age Ageing 2011, 41, 231-233.
6. Muntner, P.; Newsome, B.; Kramer, H.; Peralta, C.A.; Kim, Y.; Jacobs, D.R., Jr.; Kiefe, C.I.; Lewis, C.E. Racial Differences in the Incidence of Chronic Kidney Disease. Clin J. Am. Soc. Nephrol. 2011, 7, 101-107.
7. McCullough, K.; Sharma, P.; Ali, T.; Khan, I.; Smith, W.C.S.; MacLeod, A.; Black, C. Measuring the population burden of chronic kidney disease: A systematic literature review of the estimated prevalence of impaired kidney function. Nephrol. Dial. Transplant. 2012, 27, 1812-1821.
8. Levey, A.S.; Atkins, R.; Coresh, J.; Cohen, E.P.; Collins, A.J.; Eckardt, K.U.; Nahas, M.E.; Jaber, B.L.; Jadoul, M.; Levin A.; et al. Chronic kidney disease as a global public health problem: Approaches and initiatives-A position statement from Kidney Disease Improving Global Outcomes. Kidney Int. 2007, 72, 247-259.
9. Cusumano, A.M.; González Bedat, M.C. Chronic Kidney Disease in Latin America: Time to improve screening and detection. Clin. J. Am. Soc. Nephrol. 2008, 3, 594-600.
10. Port, F.K.; Wolfe, R.A.; Mauger, E.A.; Berling, D.P.; Jiang, K. Comparison of survival probabilities for dialysis patients vs. cadaveric renal transplantation recipients. JAMA 1993, 270, 1339-1343.
11. Evans, R.W.; Manninen, D.L.; Garrison, L.P.; Hart, L.G; Blagg, C.R.; Gutman, R.A.; Hull, A.R.; Lowrie, E.G. The quality of life of patients with end-stage renal disease. N. Engl. J. Med. 1985, 312, 553-559.
12. Eggers, P.W. Effect of transplantation on the Medicare End-Stage Renal Disease Program. N. Engl. J. Med. 1988, 318, 223-229.
13. National Kidney and Urologic Diseases Information Clearinghouse. Kidney and Urologic Diseases Statistics for the United States. Available online: http://kidney.niddk.nih.gov/kudiseases/pubs/kustats/ (accessed on 1 May 2012).
14. Kidney Disease: Improving Global Outcomes (KDIGO). Clinical practice guideline for the care of kidney transplant recipients. Am. J. Transplant. 2009, 9, S1-S155.
15. Sprangers, B.; Kuypers, D.R.; Vanrenterghem, Y. Immunosuppression: Does on regimen fit all? Transplantation 2011, 92, 251-261
16. Liberati, A.; Altman, D.G.; Tetzlaff, J.; Mulrow, C.; Gotzsche, P.C.; Loannidis, J.P.A.; Clarke, M.; Devereaux, J.K.; Moher, D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Med. 2009, 6, 7:1-7:28.
17. Woodroffe, R.; Yao, G.L.; Meads, C.; Bayliss, S.; Ready, A.; Raftery, J.; Taylor, R.S. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: A systematic review and modelling study. Health Technol. Assess. 2005, 9, 21:1-21:179.
18. Webster, A.C.; Woodroffe, R.C.; Taylor, R.S.; Chapman, J.R.; Craig, J.C. Tacrolimo versus ciclosporin as primary immunosuppression for kidney transplant recipients: Meta-analysis and meta-regression of randomised trial data. BMJ 2005, 331, 810:1-810:11.
19. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. Available online: www.cochrane-handbook.org/ (accessed on 24 June 2013).
20. Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in Meta-analyses. Available online: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm/ (accessed on 6 August 2010).
21. Higgins, J.P.T.; Thompson, S.G.; Deeks, J.J.; Altman, D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327, 557-560.
22. Scantleburry, V.; Shapiro, R.; Fung, J.; Tzakis, A.; McCauley, J.; Jordan, M.; Jensen, C.; Hakala, T.; Simmons, R.; Starzi, T.E. New onset of diabetes in FK 506 vs. cyclosporine-treated kidney transplant recipients. Transplant. Proc. 1991, 23, 3169-3170.
23. Mayer, A.D.; Dmitrewski, J.; Squifflet, J.P.; Bese, T.; Grabensee, B.; Klein, B.; Eigler, F.W.; Heemann, U.; Pichlmayr, R.; Behrend, M. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: A report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997, 64, 436-443.
24. Yang, H.C.; Holman, M.J.; Langhoff, E.; Ulsh, P.J.; Dellock, C.A.; Gupta, M.; Ahsan, N. Tacrolimus/"low-dose" mycophenolate mofetil versus microemulsion cyclosporine/"low-dose" mycophenolate mofetil after kidney transplantation: 1-year follow-up of a prospective, randomized, clinical trial. Transplant. Proc. 1999, 31, 1121-1124.
25. Wang, X.H.; Tang, X. D.; Xu, D. Tacrolimus vs. Cya Neoral in Combination with MMF and steroid after cadaveric renal transplantation. Transplant. Proc. 2000, 32, 1702-1703.
26. Nichelle, L.; Canet, S.; Garrigue, V.; Chong, G.; Mourad, G. Arterial hypertension in renal transplant recipients treated with tacrolimus or cyclosporine-Neoral. Transplant. Proc. 2002, 34, 2824-2825.
27. Campos, H.H.; Abbud, M.F. One-year follow-up of a brazilian randomized multicenter study comparing tacrolimus versus cyclosporine in kidney transplantation. Transplant. Proc. 2002, 34, 1656-1658.
28. Murphy, G.J.; Waller, J.R.; Sandford, R.S.; Furness, P.N.; Nicholson, M.L. Randomized clinical trial of the effect of microemulsion cyclosporine and tacrolimus on renal allograft fibrosis. Br. J. Surg. 2003, 90, 680-686.
29. Hardinger, K.L.; Bohl, D.L.; Schnitzler, M.A.; Lockwood, M.; Storch, G.A.; Brennan, D.C. A randomized, prospective, pharcoeconomic trial of tacrolimus versus cyclosporine in combination with thymoglobulin in renal transplant recipients. Transplantation 2005, 80, 41-46.
30. Silva, H.T., Jr.; Yang, H.C.; Abouljoud, M.; Kuo, P.C.; Wisemandle, K.; Bhattacharya, P.; Dhadda, S.; Holman, J.; Fitzsimmoms, W.; First, M.R. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am. J. Transplant. 2007, 7, 595-608.
31. Cheung, C.Y.; Chan, H.W.; Liu, Y.L.; Chau, K.F.; Li, C.S. Long-term graft function with tacrolimus and cyclosporine in renal transplantation: Paired kidney analysis. Nephrology 2009, 14, 758-763.
32. Vicenti, F.; Laskow, D.A.; Neylan, J.F.; Mendez, R.; Matas, A.J. One-year follow-up of an open-label trial of Fk506 for primary kidney transplantation: A report of the U.S. multicenter fk506 kidney transplant group. Transplantation 1996, 61, 1576-1581.
33. Moreso, F.; Serón, D.; Morales, J.M.; Cruzado, J.M.; Gil-Vernet, S.; Pérez, J.L.; Fulladosa, X.; Andrés, A.; Grinyó, J.M. Incidence of leucopenia and citomegalovirus disease in kidney transplants treated with mycophenolate mofetil combined with low cyclosporine and steroid doses. Clin. Transplant. 1998, 12, 198-205.
34. Raofi, V.; Holman, D.M.; Coady, N.; Vazquez, E.; Dunn, T.B.; Bartholomew, A.M.; Pollak, R.; Benedetti, E. A prospective randomized trial comparing the efficacy of tacrolimus versus cyclosporine in black recipients of primary cadaveric renal transplants. Am. J. Surg. 1999, 177, 299-302.
35. Sandrini, S.; Maiorca, R.; Scolari, F.; Cancarini, G.; Setti, G.; Gaggia, P.; Cristinelli, L.; Zubani, R.; Bonardelli, S.; Maffeis R.; et al. A prospective randomized trial on azathioprine addition to cyclosporine versus cyclosporine monotherapy at steroid withdrawal, 6 months after renal transplantation. Transplantation 2000, 69, 1861-1867.
36. Segoloni, G.; Bonomini, V.; Maresca, M.C.; Arisi, L.; Gonzales-Molina, M.; Tarantino, A.; del Castillo, D.; Ortuño, J.; Carmellini, M.; Capdevila L.; et al. Tacrolimus is highly effective in bith dual and triple therapy regimens following renal transplantation. Transpl. Int. 2000, 13, S336-S340.
37. Pascual, J.; Segoloni, G.; Gonzales-Molina, G.; del Castillo, D.; Capdevila, L.; Arias, M.; Garcia, J.; Ortuño, J. Comparison between a two-drug regimen with tacrolimus and steroids and a triple one with azathioprine in kidney tansplantation: Results of a European Trial with 3-year follow up. Transplant. Proc. 2003, 35, 1701-1703.
38. Chang, R.W.S.; Snowden, S.; Palmer, A.; Kwan, J.T.C.; Nocholson, M.; Kashi, S.H.; Fernando, O.N.; Perner, F.; Neild, G.H. European randomized trial of dual versus triple tacrolimus-based regimens for controlof acute rejection in renal allograft recipients. Transpl. Int. 2001, 14, 384-390.
39. Squifflet, J.P.; Bäckman, L.; Claesson, K.; Dieth, K.H.; Ekberg, H.; Dorsythe, J.L.R.; Kunsendorf, U.; Heemann, U.; Land, W.; Morales, J.M., et al. Dose Optimization of a Micophenolate Mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients. Transplantation 2001, 72, 63-69.
40. Hall, B.M.; Tiller, D.J.; Hardie, I.; Mahony, J.; Mathew, T.; Thatcher, G.; Miach, P.; Thomson, N.; Sheil, A.G. Comparison of three immunosuppressive regimens in cadaver renal transplantation: Long-term cyclosporine, short-term cyclosposrine followed by azathioprine and prednisolone, and azathioprine and prednisolone without cyclosporine. N. Engl. J. Med. 1988, 318, 1499-1507.
41. Schnuelle, P.; van der Heide, J.H.; Tegzess, A.; Verburgh, C.A.; Paul, L.C.; van der Woude, F.J.; de Fijter, J.W. Open randomized trial comparing early withdrawal of either cyclosporine or micophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen. J. Am. Soc. Nephrol. 2002, 13, 536-543.
42. Hamdy, A.F.; Bakr, M.A.; Ghoneim, M.A. Long-term efficacy and safety of a calcineurin inhibitor-free regimen in live-donor renal transplant recipients. J. Am. Soc. Nephrol. 2008, 19, 1225-1232.
43. Groth, C.G.; Bäckman, L.; Morales, J.M.; Kreis, H.; Lang, P.; Touraine, J.L.; Claesson, K.; Campistol, J.M.; Durand, D.; Wramner, L., et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Transplantation 1999, 67, 1036-1042.
44. Büchler, M.; Caillard, S.; Barbier, S.; Thervet, E.; Toupance, O.; Mazouz, H.; de Ligny, D.H.; Le Meur, Y.; Thierry, A.; Villemain, F.; et al. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am. J. Transplant. 2007, 7, 2522-2531.
45. Lebranchu, Y.; Snanoudj, R.; Toupance, O.; Weestel, P.F.; Hurault de Ligny, B.; Buchler, M.; Rerolle, J.P.; Thierry, A.; Moulin, B.; Subra, J.F., et al. Five-year results of a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation: The SPIESSER study. Am. J. Transplant. 2012, 12, 1801-1810.
46. Guba, M.; Pratschke, J.; Hugo, C.; Krämer, B.K.; Nohr-Westphal, C.; Brockman, J.; Andrassy, J.; Reinke, P.; Pressmar, K.; Hakenberg, O., et al. Renal function, efficacy, and safety of sirolimus ans mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: One-year analysis of a randomized multicenter trial. Tansplantation 2010, 90, 175-183.
47. Glotz, D.; Charpentier, B.; Abramovicz, D.; Lang, P.; Rostaing, L.; Rifle, G.; Vanrenterghem, Y.; Bethous, F.; Bourbigot, B.; Delahousse, M., et al. Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids. Transplantation 2010, 89, 1511-1517.
48. Hernández, D.; Miquel, R.; Porrini, E.; Fernández, A.; González-Posada, J.; Hortal, L.; Checa, M.D.; Rodríguez, A.; García, J.J.; Rufino, M., et al. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression. Transplantation 2007, 84, 706-714.
49. Keown, P.; Häyry, P.; Mathew, T.; Morris, P.; Stiller, C.; Barker, C.; Carr, L. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The tricontinental mycophenolate mofetil renal transplantation study group. Transplantation 1996, 61, 1029-1037.
50. Pescovitz, M.; Conti, D.; Greenstein, S.M.; Inokuchi, S.; Rosenthal, J.; Cohen, D.; Stiller, C.; Pirsch, J.; Tomlanovich, S.; Cho, S., et al. Mycophenolate Mofetil for The Treatment of a first acute renal allograft rejection. The tricontinental mycophenolate mofetil renal transplantation study group. Transplantation 1998, 65, 235-241.
51. Pescovitz, M.; Conti, D.; Greenstein, S.M.; Inokuchi, S.; Rosenthal, J.; Cohen, D.; Stiller, C.; Pirsch, J.; Tomlanovich, S.; Cho, S., et al. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: Three-year follow-up. The mycophenolate mofetil acute renal rejection study group. Transplantation 2001, 71, 1091-1097.
52. Folkmane, I.; Bicans, J.; Chapenko, S.; Murovska, M.; Rosentals, R. Results of renal transplantation with different immunosuppressive regimens. Transplant. Proc. 2002, 34, 558-559.
53. Sadek, S.; Medina, J.; Arias, M.; Sennesael, J.; Squifflet, J.P.; Vogt, B. Short-term combination of mycophenolate mofetil with cyclosporine as a therapeutic option for renal transplant recipients. Transplantation 2002, 74, 511-517.
54. Vítko, S.; Margreiter, R.; Weimar, W.; Dantal, J.; Viljoen, H.G.; Li, Y.; Jappe, A.; Cretin, N. Everolimus (Certican) 12-month safety efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 2004, 78, 1532-1540.
55. Vítko, S.; Margreiter, R.; Weimar, W.; Dantal, J.; Kuypers, D.; Winkler, M.; Oyen, O.; Viljoen, H.G.; Filiptsev, P.; Sadek, S., et al. Three-year efficacy and safety results form a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am. J. Transplant. 2005, 5, 2521-2530.
56. Lorber, M.I.; Mulgaonkar, S.; Butt, K.M.H.; Elkhammas, E.; Mendez, R.; Rajagopalan, P.R.; Kahan, B.; Solinger, H.; Li, Y.; Cretin, N., et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: A 3-year randomized, multicenter phase III study. Transplantation 2005, 80, 244-252.
57. Mendez, R.; Gonwa, T.; Yang, H.C.; Weinstein, S.; Jensik, S.; Steinberg, S. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: Results at 1 year. Transplantation 2005, 80, 303-309.
58. Sampaio, E.L.; Pinheiro-Machado, P.G.; Garcia, R.; Felipe, C.R.; Park, S.I.; Casarini, D.E.; Moreira, S.; Franco, M.F.; Tedesco-Silva, H., Jr.; Medina-Pestana, J.O. Mycophenolate mofetil vs. sirolimus in kidney transplant recipients receiving tacrolimus-based immunosuppressive regimen. Clin. Transplant. 2008, 22, 141-149.
59. Tedesco-Silva, H., Jr.; Cibrik, D.; Johnston, T.; Lackova, E.; Mange, K.; Pamos, C.; Walker, R.; Wang, Z.; Zibari, G.; Kim, Y.S. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard exposure CsA in renal-transplant patients. Am. J. Transplant. 2010, 10, 1401-1413.
60. Cibrik, D.; Silva, H.T., Jr; Vathsala, A.; Lackova, E.; Cornu-Artis, C.; Walker, RG.; Wang, Z.; Zibari, G.B.; Shihab, F.; Kim, Y.S. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation. Transplantation 2013, 95, 933-942.
61. Ekberg, H.; Tedesco-Silva, H.; Demirbas, A.; Vitko, S.; Nashan, B.; Gürkan, A.; Margreiter, R.; Hugo, C.; Grinyó, J.M.; Frei, U., et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N. Engl. J. Med. 2007, 357, 2562-2575.
62. Ekberg, H.; Bernasconi, C.; Tedesco-Silva, H.; Vitko, S.; Hugo, C.; Demirbas, A.; Acevedo, R.R.; Grinyó, J.; Frei, U.; Vamrenterghem, Y., et al. Calcineurin inhibitor minimization in the Symphony Study: Observational results 3 years after transplantation. Am. J. Transplant. 2009, 9, 1876-1885.
63. Kumar, M.S.A.; Moritz, M.J.; Saaed, M.I.; Heifets, M.; Sustento-Reodica, N.; Fyfe, B.; Kumar, A. Avoidance of chronic steroid therapy in african american kidney transplant recipients monitored by surveilance biopsy: 1-year results. Am. J. Transplant. 2005, 5, 1976-1985.
64. Tedesco-Silva, H.; Garcia, V.D.; Contieri, F.L.C.; Carvalho, D.B.M.; Noronha, I.L.; Gonçalves, R.T.; de Paula, F.J.; Abbud-Filho, M.; Manfro, R.C.; David-Neto, R. Comparison of the safety and efficacy of cyclosporine minimization versus cyclosporine elimination in de novo renal allograft patients receiving sirolimus. Transplant. Proc.2010, 42, 1659-1666.
65. Flechner, S.M.; Glyda, M.; Cockfield, S.; Grinyó, J.; Legendre, C.; Russ, G.; Steinberg, S.; Wissing, K.M.; Tai, S.S. The ORION study: Comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am. J. Transplant. 2011, 11, 1633-1644.
66. Jurewicz, W.A. Tacrolimus versus ciclosporin immunosuppression: Long-term outcome in renal transplantation. Nephrol. Dial. Transplant. 2003, 18, i7-i11.
67. Fukuhara, N.; Ono, Y.; Hattori, R.; Nishiyama, N.; Yamada, S.; Kamihira, O.; Kinukawa, T.; Ohshima, S. The long-term outcome of tacrolimus in cadaveric kidney transplantation form non-heart beating donors. Clin. Transplant. 2005, 19, 153-157.
68. Silva, L.A.; Felipe, C.R.; Park, S.I.; Pinheiro-Machado, P.; Garcia, R.; Franco, M.; Moreira, S.R.; Tedesco-Silva, H., Jr.; Medina-Pestana, J. Impact of initial exposure to calcineurin inhibitors on kidney graft function of patients at high risk to develop delayed graft function. Braz. J. Med. Biol. Res. 2006, 39, 43-52.
69. Gheith, O.A.; Bakr, M.A.; Fouda, M.A.; Shokeir, A.A.; Bayoumy, A.; Sobh, M.; Ghoneim, M. Steroid and azathioprine versus steroid, cyclosporine, and azathioprine therapies in primary haplo-identical living donor kidney transplantation: Twenty-year experience. Iran J. Kidney Dis. 2008, 2, 34-39.
70. Cotovio, P.; Neves, M.; Rodrigues, L.; Alves, R.; Bastos, M.; Baptista, C.; Macário, F.; Mota, A. New-onset diabetes after transplantation: Assessment of risk factors and clinical outcomes. Transplant. Proc. 2013, 45, 1079-1083.
71. Knight, S.R.; Russell, N.K.; Barcena, L.; Morris, P.J. Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: A systematic review. Transplantation 2009, 87, 785-794.
72. Van Hooff, J.P.; Squifflet, J.P. A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal transplant recipients. Transplantation 2003, 75, 1934-1939.
73. Webster, A.C.; Lee, V.W.; Chapman, J.R.; Craig, J.C. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: A systematic review and meta-analysis of randomized trials. Transplantation 2006, 81, 1234-1248.
74. Johnston, O.; Rose, C.L.; Webster, A.C.; Gill, J.S. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J. Am. Soc. Nephrol. 2008, 19, 1411-1418.
75. Danovitch, G.M. Immunosuppressive Medications and Protocols for Kidney Transplantation. In Handbook of Kidney Transplantation, 4th ed.; Danovitch, G.M., Eds.; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2005, pp. 72-134.
76. Ribes, D.; Kamar, N. Combined use of tacrolimus and sirolimus in de novo renal transplant patients: Current data. Transplant. Proc. 2005, 37, 2813-2816
77. Gralla, J.; Wiseman, A.C. Tacrolimus/sirolimus versus tacrolimus/mycophenolate in kidney transplantation: Improved 3-year graft and patient survival in recent era. Transplantation 2009, 87, 1712-1719.
78. Yabu, J.M.; Vincenti, F. Kidney Transplantation: The ideal immunosuppression regimen. Adv. Chronic Kidney Dis. 2009, 16, 226-233.